BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH lowered its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 1.7% during the fourth quarter, Holdings Channel.com reports. The fund owned 715,500 shares of the biotechnology company’s stock after selling 12,170 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in BioMarin Pharmaceutical were worth $47,030,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Susquehanna Fundamental Investments LLC acquired a new position in shares of BioMarin Pharmaceutical in the 2nd quarter valued at about $5,627,000. Teachers Retirement System of The State of Kentucky lifted its position in BioMarin Pharmaceutical by 17.4% during the second quarter. Teachers Retirement System of The State of Kentucky now owns 194,207 shares of the biotechnology company’s stock valued at $15,990,000 after buying an additional 28,837 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in BioMarin Pharmaceutical by 461.3% during the fourth quarter. Assenagon Asset Management S.A. now owns 611,667 shares of the biotechnology company’s stock valued at $40,205,000 after buying an additional 502,695 shares in the last quarter. Wedmont Private Capital purchased a new stake in BioMarin Pharmaceutical during the fourth quarter worth approximately $430,000. Finally, EULAV Asset Management increased its position in shares of BioMarin Pharmaceutical by 12.9% in the third quarter. EULAV Asset Management now owns 131,000 shares of the biotechnology company’s stock worth $9,208,000 after acquiring an additional 15,000 shares in the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on BMRN shares. Raymond James reaffirmed an “outperform” rating and set a $79.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, October 10th. Wolfe Research started coverage on BioMarin Pharmaceutical in a research report on Friday, November 15th. They issued an “outperform” rating and a $95.00 target price for the company. Canaccord Genuity Group dropped their target price on BioMarin Pharmaceutical from $93.00 to $84.00 and set a “hold” rating on the stock in a report on Wednesday, October 30th. Wedbush upgraded BioMarin Pharmaceutical to a “strong-buy” rating in a report on Monday, November 4th. Finally, UBS Group lifted their price objective on shares of BioMarin Pharmaceutical from $104.00 to $106.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Seven equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $94.20.

Insider Transactions at BioMarin Pharmaceutical

In other news, EVP Charles Greg Guyer sold 5,278 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $66.37, for a total transaction of $350,300.86. Following the completion of the transaction, the executive vice president now owns 68,909 shares of the company’s stock, valued at approximately $4,573,490.33. The trade was a 7.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 1.85% of the company’s stock.

BioMarin Pharmaceutical Stock Up 1.6 %

BMRN stock opened at $62.53 on Wednesday. The firm has a fifty day moving average price of $65.39 and a two-hundred day moving average price of $74.15. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62. BioMarin Pharmaceutical Inc. has a 1-year low of $60.63 and a 1-year high of $94.85. The firm has a market cap of $11.92 billion, a price-to-earnings ratio of 37.44, a PEG ratio of 0.54 and a beta of 0.29.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.23). BioMarin Pharmaceutical had a net margin of 11.71% and a return on equity of 8.53%. The business had revenue of $746.00 million for the quarter, compared to the consensus estimate of $703.37 million. During the same period in the prior year, the company earned $0.26 EPS. BioMarin Pharmaceutical’s quarterly revenue was up 28.4% on a year-over-year basis. Research analysts predict that BioMarin Pharmaceutical Inc. will post 2.5 EPS for the current year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.